Enhancement of quiet sleep in XXXX neonates by @entity7191 .

@entity7192 @entity95 @entity7193 @entity7191 @entity25
@entity7193 peptides that induce excess slow-wave sleep have been isolated from urine and brain. A synthetic analogue to those substances, @entity7191 ( @entity7192 , @entity7191 ), was found to induce prolonged increases in slow-wave sleep and to increase electroencephalographic (EEG) delta-wave activity. @entity7192 is also pyrogenic, although this activity can be separated from its somnogenic activity. To further investigate the somnogenic actions of @entity7192 , neonatal @entity95 were used in the present study. Intraperitoneal injection of 100 micrograms/kg @entity7192 induced differential somnogenic and pyrogenic effects; from postnatal days 7-9, @entity7192 increased duration of quiet sleep (QS, the precursor of adult slow-wave sleep) and @entity25 ( @entity25 ) as judged by behavioral criteria. These animals were not febrile during the period of enhanced QS, nor did @entity7192 alter EEG delta-wave activity at this age. From postnatal days 10-15, @entity7192 induced prolonged (6 h) increases in duration of QS; both behavioral and EEG criteria were used at this age to determine duration of QS and @entity25 . Maximum @entity7192 -induced effects occurred during the 2nd h, with a parallel increase in amplitudes of EEG delta-wave activity. At this age, @entity7192 also elicited monophasic fevers and inhibition of @entity25 , with maximum effects observed during hours 3-4 postinjection. After postnatal day 16, @entity7192 -induced somnogenic and febrile responses were similar to those observed in adult @entity95 . We conclude that the mechanisms responsible for behavioral sleep states are responsive to a sleep-promoting substance early in ontogenesis.
